Lentivirus Production CDMO Services

Do you need your lentiviral vector as starting material for cell therapy and/or a lentivirus as a drug product?

Whether you want to develop or produce your lentivirus vector, we can help you!

Our end-to-end CDMO services, spanning vector design to GMP-compliant manufacturing, leverage our proprietary Lenti.RiGHT^® packaging and producer cell line. This ensures high titers, stable vectors, and cost-efficient solutions, streamlining your path to seamless scale-up and commercialization.

We offer integrated CDMO services to develop and manufacture lentiviral vectors. We can produce the viral vector by transient transfection, packaging, or producer cell line.

As one stop-shop we cover all steps, from vector design and development to process development and GMP manufacturing to analytics, bioassays, QC and fill & finish.

We rely on our Lenti.RiGHT^® packaging cell line as a production system to unlock the full potential of your lentiviral vector construct. Choose what works best for you from our flexible development and manufacturing services.

Vector Design and Development

Process Development (DSP/USP)

(GMP) Manufacturing*

Quality Control & Analytics

Transient Transfections for Lentiviral Vector Production

Ideal Use Case: Early Phase Clinical Trial

Rapid Production Cycle: Transient transfection allows for the rapid production of lentiviral vectors, making it ideal for applications requiring quick turnaround times, such as early-phase (pre)clinical trials or urgent research needs.
Flexibility: This method provides high flexibility in changing vector designs and when incorporating genetic modifications. Researchers can easily adapt to different constructs without the need for long development cycles.
Scalability: Though traditionally seen as less scalable than stable cell lines, advancements in transient transfection techniques have significantly improved yields, making them feasible for larger-scale productions.
Reduced Development Time: Bypassing the need for generating stable cell lines cuts down on the time required to initiate production. This allows for faster project initiation and delivery.

Lenti.RiGHT^® Packaging Cell Line

Ideal Use Case: High-Titer Viral Production for Research and Early Clinical Studies

Flexibility in Vector Design: Packaging cells without the stable integration of the lentiviral transfer vector allow for quick changes to the transfer vector, thereby providing adaptability for different therapeutic applications.

Streamlined Process: This approach simplifies the production process by focusing on the generation of high-titer viral particles without the complications involved with integrating the lentiviral transfer vector into the packaging cell line.

High-Titer Production: These cells are optimized for high-titer viral production, making them suitable for producing sufficient quantities of vectors for research and early clinical studies.

Lenti.RiGHT^® Producer Cell Line

Ideal Use Case: Later-Phase Clinical Trials and Commercial Production

Consistency and Reproducibility: With all lentiviral packaging genes and the transfer vector stably integrated, these production cells ensure consistent vector production, which is critical for clinical applications where batch-to-batch variability must be minimized.
High Yield and Efficiency: These cells are engineered for optimal expression of all necessary components, which leads to high-yield production suitable for the large-scale manufacturing needed in later-phase clinical trials and commercial production.
Simplified Manufacturing: The stable integration of all components streamlines the manufacturing process, thereby reducing the complexity and variability associated with transient transfections and ensuring a more robust production pipeline.
Cost-Effectiveness: Over time, the use of these stable production cell lines can be more cost-effective thanks to reduced variability, elimination of the need for repeated transfections, and consistently high yields. This all leads to lower overall production costs.

The Lenti.RiGHT^®packaging and producer cell line is well suited for the efficient and reliable production of lentiviral vectors. This lentivirus production platform is based on our GMP-grade HEK293 suspension cell, which is stably transfected with all required viral components. The inducible system enables a scalable and efficient production of high-titer lentiviral particles for various applications starting from early in vitro demonstration testing and preclinical studies through to gene and cell therapies in a clinical environment. 